Good MorningEquity markets started the holiday-shortened week on solid footing, advancing incrementally to hover near record highs. The move was partly supported by President-elect Trump's pick of Scott Bessent for Treasury Secretary. The market favors the pick because his economic views will temper Donald Trump's more aggressive stance and reduce the risk of inflation accelerating.
The hurdle for markets this week is Wednesday. The economic calendar contains market-moving reports, including the Fed minutes and PCE price index. The PCE price index is expected to reveal inflation accelerating at the headline and core levels, contradicting the trend that led the FOMC to cut rates in September. This will be the second month inflation has increased since the Fed first cut rates, and it will likely keep them from cutting again in December, news that may keep the S&P 500 from hitting another new high this year. Featured: Your Money Is Now ‘Government Property’ (Their Words) (Ad) 
|
Markets | | |
Retail investors often feel on the outside of the stock market since information can often be hard to access and digest when the factors and trends to be identified aren’t too clear-cut. This is why looking at Wall Street analyst actions can be an important checklist for retail investors whe... Read the Full Story |
|
From Our Partners | | Tariffs and trade tensions are back in the headlines, and while many are focused on the risks, smart investors know there’s also opportunity.
New supply chain shifts, pricing power adjustments, and sector revaluations are already underway—creating openings for those who act early.
That’s why we’ve just released our latest research:
📈 “From Tariffs to Returns: How to Capitalize on Trade Disputes in Your Portfolio” | | Position yourself ahead of the next move—get the full report here. |
|
Stocks | | | U.S. stocks rose to records Tuesday after Donald Trump’s latest talk about tariffs created only some ripples on Wall Street, even if they could roil the global economy were they to take effect.The S&P 500 climbed 0.6% to top the all-time high it set a couple weeks ago. The Dow Jones Industrial... Read the Full Story |
|
Stocks | | | U.S. stocks rose Monday, with those benefiting the most from lower interest rates and a stronger economy leading the way.The S&P 500 climbed 0.3% to pull closer to its all-time high set two weeks ago. The Dow Jones Industrial Average added 440 points, or 1%, to its own record set on Friday, whil... Read the Full Story |
|
From Our Partners | | How to Collect Up To $5,917/mo From Trump's Made In USA Boom
Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America.
But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month.
Don't miss your chance to participate directly in America's industrial comeback. | | Watch Now to Learn How to Get Your First Check in 30 Days |
|
Markets | | |
With the Trump administration taking over in January 2025, there has been much speculation about forthcoming changes, trends, and themes. With Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk firmly embedded in Trump’s inner circle, there’s been speculation that self-driving or autonomous cars ... Read the Full Story |
|
Markets | | | Investor Warren Buffett renewed his Thanksgiving tradition of giving by handing out more than $1.1 billion of Berkshire Hathaway stock to four of his family's foundations Monday, and he offered new details about who will be handing out the rest of his fortune after his death Read the Full Story |
|
From Our Partners | | Summer is almost Here! I would like to give you a special report that could help boost your portfolio this summer (and beyond).
It’s called 7 Best Stocks to Own in Summer 2025.
These are companies that not only thrive in the summer but are capable of generating juicy returns throughout the year.
To get it, just click the link below… but don’t dally, this is a limited-time offer. | | Get Your Copy of "7 Best Stocks to Own in Summer 2025" Here. |
|
Markets | | |
Following the 2024 U.S. election, there has been a great deal of speculation about how a second Trump administration will set policies that have an impact on the economy. Some have taken a strongly optimistic view of what's to come—a recent Goldman Sachs report suggested that the likelihood ... Read the Full Story |
|
Markets | | |
Abacus Life, Inc. (NASDAQ: ABL) is a global alternative asset manager specializing in a unique niche within the financial markets. The company acquires and manages life insurance policies.
The company's core mission is to generate financial returns for investors and educate consumers on the of... Read the Full Story |
|
Markets | | | Wall Street is betting corporate dealmaking could bounce back next year if the new Trump administration ushers in lower interest rates and looser regulatory scrutiny. The number of deals and their value are both below pre-pandemic levels. In the U.S., deal values fell 23% in 2023 from just before th... Read the Full Story |
|
Markets | | | Bath & Body Works fiscal third-quarter performance topped analysts' estimates thanks to strong sales, and the retailer boosted its full-year outlook.The owner of Victoria’s Secret, Bath & Body Works and other chain stores earned $106 million, or 49 cents per share, for the period. A year ear... Read the Full Story |
|
Markets | | |
Investing in companies in their first year of being publicly traded can be an exciting and perilous proposition. It may take time for enough information to come out about a new stock before the market can gather a strong sense of its actual value, leading to volatility. Shares can see large uptick... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California. | Should I Buy Gilead Sciences Stock? GILD Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Gilead Sciences was last updated on Saturday, July 05, 2025 at 6:28 PM.
Gilead Sciences Bull Case -
The stock has received multiple "overweight" ratings from analysts, indicating strong confidence in its potential for growth.
-
Recent price targets from analysts suggest a positive outlook, with some estimates reaching as high as $135.00, which could indicate significant upside potential.
-
The current stock price is around $110, which may be seen as an attractive entry point for investors looking for value.
-
Gilead Sciences, Inc. has a diverse portfolio of medicines addressing unmet medical needs, which can provide stability and growth opportunities in the biopharmaceutical sector.
-
Insider ownership, although low, indicates that company executives have a vested interest in the company's performance, which can align their goals with those of shareholders.
Gilead Sciences Bear Case -
Insider selling has been notable, with 58,500 shares sold recently, which may raise concerns about the executives' confidence in the company's future performance.
-
Despite positive ratings, the stock has a consensus rating of "Moderate Buy," which may suggest that some analysts are cautious about its near-term prospects.
-
Recent price target adjustments have shown some downward revisions, indicating that analysts may have concerns about the company's growth trajectory.
-
With only 0.27% of the stock owned by insiders, there may be a lack of strong internal support for the stock's performance, which can be a red flag for investors.
-
The biopharmaceutical industry is highly competitive and subject to regulatory changes, which can impact Gilead Sciences, Inc.'s market position and profitability.
| | View Today's Stock Pick |
|
